Possible drug targets for common non-Hodgkin's lymphoma discovered

Researchers have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma, according to a new study. The scientists report that they have found a complex relationship between ERK, a protein that helps to regulate cell survival, and CHK2, a protein involved in the cellular DNA damage response.

Read the whole article on Science Daily

More from Science Daily